Spruance S L, Stewart J C, Rowe N H, McKeough M B, Wenerstrom G, Freeman D J
Department of Medicine, School of Medicine, University of Utah, Salt Lake City 84132.
J Infect Dis. 1990 Feb;161(2):185-90. doi: 10.1093/infdis/161.2.185.
In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114, 25%) than among placebo-treated subjects (29/60, 48%; P = .004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the patients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36% (P = .02) and the mean healing time to loss of crust by 27% (P = .03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.
在一项双盲、随机、患者发起的临床试验中，174名有病毒培养确诊的唇疱疹病史的非免疫功能低下患者接受了阿昔洛韦胶囊治疗（每日5次，每次400mg，共5天）或安慰剂胶囊治疗。97%的患者在复发的首个体征或症状出现后1小时内开始治疗。阿昔洛韦治疗组患者中病变病毒培养阳性的频率（29/114，25%）显著低于安慰剂治疗组（29/60，48%；P = 0.004）。药物治疗并未影响病变的发展，通过斑疹和丘疹（未进展）病变的频率以及平均最大病变大小来衡量。然而，阿昔洛韦加速了在前驱期或红斑病变期开始治疗的患者的病变消退。对于该组患者，疼痛的平均持续时间缩短了36%（P = 0.02），结痂脱落的平均愈合时间缩短了27%（P = 0.03）。因此，口服阿昔洛韦减轻了唇疱疹的一些临床表现。
